Study of Clonal Hematopoiesis as a Risk Factor for Chemotherapy Complications in Lymphoma Patients Aged 60 and Older

What this Trial Is About

Researchers are investigating whether Clonal Hematopoiesis of Indeterminate Significance CHIP, which involves mutations in bone marrow stem cells that give certain cells a growth advantage, is a risk factor for chemotherapy-related complications in lymphoma patients aged 60 years and older. CHIP is known to increase with age and is linked to cardiovascular disease and bone marrow cancers. This study aims to understand if CHIP contributes to problems like low blood counts, infections, heart events, hospitalizations, chemotherapy dose delays or reductions, and poor blood count recovery after chemotherapy. Participants are lymphoma patients aged 60 and above who are starting their first or second line of cytotoxic chemotherapy, with or without rituximab. The study involves an additional blood test to analyze DNA for the presence of CHIP mutations. This observational study follows patients to see if CHIP is connected to chemotherapy complications and changes in blood cell development over time. During the study, participants will be monitored for up to 24 weeks to determine if CHIP predicts chemotherapy complications and up to 12 months to observe emerging blood cell abnormalities after treatment. Secondary outcomes like the growth of clonal stem cells, development of therapy-related bone marrow cancers, and overall survival will be tracked for up to 5 years. Researchers collect medical data and blood samples to assess these outcomes and better understand how CHIP affects treatment response and patient health.

Clonal Hematopoiesis is a Risk Factor for Chemotherapy-Related Complications